Australia · Delayed Price · Currency is AUD Integral Diagnostics Earnings Call Transcripts
Fiscal Year 2026
-
Revenue grew 55.6% to AUD 393.5 million, with EBITDA margin up 230 bps to 20.6% and strong synergy realization from the Capitol merger. Ongoing investments in AI, teleradiology, and new sites support further growth, while integration costs are trending down.
Fiscal Year 2025
-
The meeting highlighted strong revenue and margin growth, successful Capital Health integration, and robust sustainability and governance initiatives. Shareholders approved new directors, CEO incentives, and a special resolution, while Q&A addressed radiologist retention, AI, and future growth.
-
Revenue grew 33.7% to $628M, driven by the Capital Health merger and organic growth, with EBITDA margin up to 20.1%. Annualized merger synergies are now $14M, and FY 2026 guidance points to further margin and revenue expansion, supported by MRI deregulation and new screening programs.
-
Revenue and EBITDA grew solidly year-over-year, with strong NPAT and free capital flow increases. Merger integration with Capitol is progressing, targeting AUD 10 million in synergies, while regulatory changes and new screening programs are expected to drive future growth.
Fiscal Year 2024
-
The AGM covered a year of solid operational improvement, with revenue and EBITDA growth despite a statutory loss from a New Zealand impairment. Strategic focus included a major merger, board renewal, and ESG progress. All resolutions were presented and voting proceeded smoothly.
-
Revenue grew 6.6% to AUD 469.7 million and operating EBITDA rose 7.4% to AUD 91.5 million, with improved margins and reduced leverage. Statutory net loss was driven by a large New Zealand impairment, but operating NPAT increased. A merger with Capitol Health is expected to deliver significant synergies and EPS accretion.
-
A transformative merger will create a leading diagnostic imaging provider in ANZ, combining complementary networks and unlocking at least AUD 10 million in annual cost synergies. The deal is expected to deliver double-digit EPS accretion, with minimal regulatory hurdles anticipated.
-
A merger is proposed to create a leading diagnostic imaging group in Australia and New Zealand, offering significant scale, clinical depth, and at least AUD 10 million in annual cost synergies. The deal is structured as a share exchange, with integration and regulatory approvals expected over several months.